All Updates

All Updates

icon
Filter
Partnerships
BioMap partners with GeneQuantum to co-develop ADC therapeutics
AI Drug Discovery
Dec 14, 2023
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
AI Drug Discovery

AI Drug Discovery

Dec 14, 2023

BioMap partners with GeneQuantum to co-develop ADC therapeutics

Partnerships

  • China-based AI research company BioMap and drug developer GeneQuantum Healthcare have collaborated to co-develop targeted Antibody-Drug Conjugate (ADC) therapeutics. The terms and financial details of the agreement have not been disclosed.

  • The partnership will merge GeneQuantum's proprietary enzymatic site-specific conjugation technology platforms (iLDC-intelligent ligase-dependent conjugation and iGDC-intelligent Glycotransferase-dependent conjugation) with BioMap's large AI model and protein generation platform (AIGP) to develop new ADC therapies. By integrating their expertise in high-quality data mining and utilization, cross-model data integration and analysis, target discovery, and antibody design, the companies aim to address global unmet clinical needs with ADC drugs. 

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.